| Date Filed | Type | Description |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/10/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Exercised (in-or-at-the-money) 57,049 options to buy
@ $0
Exercised (in-or-at-the-money) 535,601 options to buy
@ $0 |
|
| 10/05/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/28/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 08/17/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 20% stake in Neoleukin Therapeutics, Inc. |
| 08/17/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Bought 143,519 shares
@ $0.6308, valued at
$90.5k
Bought 1,740,581 shares
@ $0.6308, valued at
$1.1M
Bought 358 shares
@ $0.665, valued at
$238.1
Bought 4,342 shares
@ $0.665, valued at
$2.9k
Bought 17,124 shares
@ $0.6805, valued at
$11.7k
Bought 207,676 shares
@ $0.6805, valued at
$141.3k
Bought 366 shares
@ $0.6828, valued at
$249.9
Bought 4,434 shares
@ $0.6828, valued at
$3k
Bought 7,676 shares
@ $0.6924, valued at
$5.3k
Bought 93,091 shares
@ $0.6924, valued at
$64.5k
Bought 5,041 shares
@ $0.6928, valued at
$3.5k
|
|
| 08/14/2023 |
4
| Smith Sean Michael (Interim CFO, Prin Acct Off) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Sold 1,323 shares
@ $0.6184, valued at
$818.1
Exercised 5,000 restricted stock units
@ $0 |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/27/2023 |
SC 13D
| Redmile Group, LLC reports a 6.6% stake in NEOLEUKIN THERAPEUTICS, INC. |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/18/2023 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Agreement and Plan of Merger, by and among Neoleukin Therapeutics, Inc., Project North Merger Sub, Inc. and Neurogene Inc",
"Form of Contingent Value Rights Agreement",
"Form of Neurogene Support Agreement",
"Form of Neoleukin Support Agreement",
"Form of Lock-Up Agreement",
"Letter Agreement, by and between Neoleukin Therapeutics, Inc. and Baker Bros. Advisors LP",
"NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT",
"Investor Presentation, dated July 2023" |
|
| 06/12/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/09/2023 |
4
| SIMPSON TODD E (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 06/09/2023 |
4
| PALEKAR ROHAN (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 06/09/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 06/09/2023 |
4
| Lavelle Erin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 06/09/2023 |
4
| Babler Martin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/04/2023 |
4
| Patel Priti (Former Chief Medical Officer) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Sold 3,769 shares
@ $0.6919, valued at
$2.6k
Exercised 10,000 restricted stock units
@ $0 |
|
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/20/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 03/08/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
SC 13G
| PICTET ASSET MANAGEMENT SA reports a 0% stake in Neoleukin Therapeutics Inc. |
| 01/23/2023 |
8-K/A
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
|